Cargando…
Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts
This policy research aims to map patient access barriers to biologic treatments, to explore how increased uptake of biosimilars may lower these hurdles and to identify factors limiting the increased utilisation of biosimilars. A policy survey was developed to review these questions in 10 Central and...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818964/ https://www.ncbi.nlm.nih.gov/pubmed/29546072 http://dx.doi.org/10.1155/2018/9597362 |
_version_ | 1783301120693633024 |
---|---|
author | Inotai, Andras Csanadi, Marcell Petrova, Guenka Dimitrova, Maria Bochenek, Tomasz Tesar, Tomas York, Kristina Fuksa, Leos Kostyuk, Alexander Lorenzovici, Laszlo Omelyanovskiy, Vitaly Egyed, Katalin Kalo, Zoltan |
author_facet | Inotai, Andras Csanadi, Marcell Petrova, Guenka Dimitrova, Maria Bochenek, Tomasz Tesar, Tomas York, Kristina Fuksa, Leos Kostyuk, Alexander Lorenzovici, Laszlo Omelyanovskiy, Vitaly Egyed, Katalin Kalo, Zoltan |
author_sort | Inotai, Andras |
collection | PubMed |
description | This policy research aims to map patient access barriers to biologic treatments, to explore how increased uptake of biosimilars may lower these hurdles and to identify factors limiting the increased utilisation of biosimilars. A policy survey was developed to review these questions in 10 Central and Eastern European (CEE) and Commonwealth of Independent States (CIS) countries. Two experts (one public and one private sector representative) from each country completed the survey. Questions were related to patient access, purchasing, clinical practice, and real-world data collection on both original biologics and biosimilars. Restrictions on the number of patients that can be treated and related waiting lists were reported as key patient access barriers. According to respondents, for both clinicians and payers the primary benefit of switching patients to biosimilars would be to treat more patients. However, concerns with therapeutic equivalence and fear of immunogenicity may reduce utilisation of biosimilars. Similar limitations in patient access to both original biologics and biosimilars raise concerns about the appropriateness and success of current biosimilar policies in CEE and CIS countries. The conceptual framework for additional real-world data collection exists in all countries which may provide a basis for future risk-management activities including vigorous pharmacovigilance data collection. |
format | Online Article Text |
id | pubmed-5818964 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-58189642018-03-15 Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts Inotai, Andras Csanadi, Marcell Petrova, Guenka Dimitrova, Maria Bochenek, Tomasz Tesar, Tomas York, Kristina Fuksa, Leos Kostyuk, Alexander Lorenzovici, Laszlo Omelyanovskiy, Vitaly Egyed, Katalin Kalo, Zoltan Biomed Res Int Research Article This policy research aims to map patient access barriers to biologic treatments, to explore how increased uptake of biosimilars may lower these hurdles and to identify factors limiting the increased utilisation of biosimilars. A policy survey was developed to review these questions in 10 Central and Eastern European (CEE) and Commonwealth of Independent States (CIS) countries. Two experts (one public and one private sector representative) from each country completed the survey. Questions were related to patient access, purchasing, clinical practice, and real-world data collection on both original biologics and biosimilars. Restrictions on the number of patients that can be treated and related waiting lists were reported as key patient access barriers. According to respondents, for both clinicians and payers the primary benefit of switching patients to biosimilars would be to treat more patients. However, concerns with therapeutic equivalence and fear of immunogenicity may reduce utilisation of biosimilars. Similar limitations in patient access to both original biologics and biosimilars raise concerns about the appropriateness and success of current biosimilar policies in CEE and CIS countries. The conceptual framework for additional real-world data collection exists in all countries which may provide a basis for future risk-management activities including vigorous pharmacovigilance data collection. Hindawi 2018-01-10 /pmc/articles/PMC5818964/ /pubmed/29546072 http://dx.doi.org/10.1155/2018/9597362 Text en Copyright © 2018 Andras Inotai et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Inotai, Andras Csanadi, Marcell Petrova, Guenka Dimitrova, Maria Bochenek, Tomasz Tesar, Tomas York, Kristina Fuksa, Leos Kostyuk, Alexander Lorenzovici, Laszlo Omelyanovskiy, Vitaly Egyed, Katalin Kalo, Zoltan Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts |
title | Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts |
title_full | Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts |
title_fullStr | Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts |
title_full_unstemmed | Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts |
title_short | Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts |
title_sort | patient access, unmet medical need, expected benefits, and concerns related to the utilisation of biosimilars in eastern european countries: a survey of experts |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818964/ https://www.ncbi.nlm.nih.gov/pubmed/29546072 http://dx.doi.org/10.1155/2018/9597362 |
work_keys_str_mv | AT inotaiandras patientaccessunmetmedicalneedexpectedbenefitsandconcernsrelatedtotheutilisationofbiosimilarsineasterneuropeancountriesasurveyofexperts AT csanadimarcell patientaccessunmetmedicalneedexpectedbenefitsandconcernsrelatedtotheutilisationofbiosimilarsineasterneuropeancountriesasurveyofexperts AT petrovaguenka patientaccessunmetmedicalneedexpectedbenefitsandconcernsrelatedtotheutilisationofbiosimilarsineasterneuropeancountriesasurveyofexperts AT dimitrovamaria patientaccessunmetmedicalneedexpectedbenefitsandconcernsrelatedtotheutilisationofbiosimilarsineasterneuropeancountriesasurveyofexperts AT bochenektomasz patientaccessunmetmedicalneedexpectedbenefitsandconcernsrelatedtotheutilisationofbiosimilarsineasterneuropeancountriesasurveyofexperts AT tesartomas patientaccessunmetmedicalneedexpectedbenefitsandconcernsrelatedtotheutilisationofbiosimilarsineasterneuropeancountriesasurveyofexperts AT yorkkristina patientaccessunmetmedicalneedexpectedbenefitsandconcernsrelatedtotheutilisationofbiosimilarsineasterneuropeancountriesasurveyofexperts AT fuksaleos patientaccessunmetmedicalneedexpectedbenefitsandconcernsrelatedtotheutilisationofbiosimilarsineasterneuropeancountriesasurveyofexperts AT kostyukalexander patientaccessunmetmedicalneedexpectedbenefitsandconcernsrelatedtotheutilisationofbiosimilarsineasterneuropeancountriesasurveyofexperts AT lorenzovicilaszlo patientaccessunmetmedicalneedexpectedbenefitsandconcernsrelatedtotheutilisationofbiosimilarsineasterneuropeancountriesasurveyofexperts AT omelyanovskiyvitaly patientaccessunmetmedicalneedexpectedbenefitsandconcernsrelatedtotheutilisationofbiosimilarsineasterneuropeancountriesasurveyofexperts AT egyedkatalin patientaccessunmetmedicalneedexpectedbenefitsandconcernsrelatedtotheutilisationofbiosimilarsineasterneuropeancountriesasurveyofexperts AT kalozoltan patientaccessunmetmedicalneedexpectedbenefitsandconcernsrelatedtotheutilisationofbiosimilarsineasterneuropeancountriesasurveyofexperts |